Skip to main content
Evidence Snapshot

Bcl-2-like protein 1

CHEMBL4625 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:21:02Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4625
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bcl-2-like protein 1 as ChEMBL target CHEMBL4625, mapped to UniProt Q07817. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Bcl-2-like protein 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4625
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q07817
Bcl-2-like protein 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Bcl-2-like protein 1 matters

As of 2026-09-13

Bcl-2-like protein 1 is reviewed as Bcl-2-like protein 1 (UniProt Q07817); Bcl-2-like protein 1 shows late clinical disease relevance led by small cell lung carcinoma. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 4 approved drugs, 2415 compounds, and 353 assays, with lead potency reaching pChEMBL 11.0.

Disease context
small cell lung carcinoma

Bcl-2-like protein 1 shows late clinical disease relevance led by small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include NAVITOCLAX, OBATOCLAX MESYLATE.

Start review with small cell lung carcinoma because it currently carries late clinical support. Linked drugs include NAVITOCLAX, OBATOCLAX MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 4 approved drugs, 2415 compounds, and 353 assays for this target. The dominant activity type is IC50. CHEMBL3342333 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL3342333 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
4 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Bcl-2-like protein 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q07817, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why small cell lung carcinoma is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2415
Total Compounds
353
Total Assays
4
Approved Drugs
IC50: 1588.0, KI: 1175.0, EC50: 210.0, KD: 163.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3342333
 11.0 Ki —
No preferred name
CHEMBL3342197
 10.7 Ki —
No preferred name
CHEMBL3935328
 10.6 Ki —
No preferred name
CHEMBL3342196
 10.5 Ki —
No preferred name
CHEMBL3342334
 10.5 Ki —

Approved Drugs

Structure Compound First Approval
VENETOCLAX
CHEMBL3137309
 2016
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:21:02Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4625